Related Experiment Video

Updated: Oct 5, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 28, 2007

Adrenoleukodystrophy: a fatal disorder with new opportunities for prevention and treatment

S O'Donnell-O'Toole

    Journal of Neurosurgical Nursing
    |February 1, 1985
    PubMed

    Insights

    Adrenoleukodystrophy is an X-linked condition causing adrenal insufficiency and brain demyelination, primarily affecting young boys. Current management focuses on symptomatic treatment and comprehensive nursing care, as diagnostic and prenatal testing are available.

    Area of Science:

    • Genetics and Neurology
    • Biochemical disorders

    Background:

    • Adrenoleukodystrophy (ALD) is a rare X-linked genetic disorder.
    • It is characterized by adrenal insufficiency and progressive demyelination of the cerebral white matter.
    • ALD typically manifests in young boys during early school years, leading to a progressive, often fatal, neurological decline.

    Purpose of the Study:

    • To provide an overview of Adrenoleukodystrophy (ALD).
    • To highlight the availability of diagnostic, carrier, and prenatal testing options.
    • To discuss current symptomatic treatment approaches and the comprehensive nursing care required for ALD patients.

    Main Methods:

    • Literature review of Adrenoleukodystrophy.
    • Synthesis of information on diagnostic methods and genetic testing.
    • Compilation of current treatment strategies and nursing care principles.

    Main Results:

    • Diagnostic, carrier, and prenatal testing for ALD are established.
    • Current therapeutic interventions for ALD are primarily symptomatic.
    • Comprehensive nursing care addresses physical, emotional, and familial needs.

    Conclusions:

    • Adrenoleukodystrophy requires early diagnosis and management.
    • While a cure is not yet available, symptomatic treatment and specialized nursing care can improve patient quality of life.
    • Ongoing research is crucial for advancing ALD treatment and understanding.

    More Related Videos

    An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy07:45

    An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

    Published on: October 21, 2014

    Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells06:20

    Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

    Published on: May 7, 2020

    Related Concept Videos

    Parkinson's Disease: Overview01:15

    Parkinson's Disease: Overview

    Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
    Alzheimer's Disease: Treatment01:22

    Alzheimer's Disease: Treatment

    Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
    Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

    Acute Kidney Injury IV: Diagnostic Studies and Prevention

    Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
    Alzheimer Disease l: Introduction01:29

    Alzheimer Disease l: Introduction

    Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
    Huntington Disease l: Introduction01:21

    Huntington Disease l: Introduction

    Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...